NXD 02
Alternative Names: NXD-02Latest Information Update: 05 Mar 2024
At a glance
- Originator neoX Biotech
- Class Antineoplastics
- Mechanism of Action Bcl-X protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical B-cell lymphoma; Ovarian cancer; Small cell lung cancer; T-cell lymphoma
Most Recent Events
- 30 Jan 2024 Preclinical trials in B-cell lymphoma in China (IV), before January 2024 (neoX Biotech pipeline, January 2024)
- 30 Jan 2024 Preclinical trials in Ovarian cancer in China (IV), before January 2024 (neoX Biotech pipeline, January 2024)
- 30 Jan 2024 Preclinical trials in Small cell lung cancer in China (IV), before January 2024 (neoX Biotech pipeline, January 2024)